Display options
Cite
Badar VA, Hiware SK, Shrivastava MP, et al. Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension. Indian J Pharmacol. 2011;43(4):437-40doi: 10.4103/0253-7613.83117.
Badar, V. A., Hiware, S. K., Shrivastava, M. P., Thawani, V. R., & Hardas, M. M. (2011). Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension. Indian journal of pharmacology, 43(4), 437-40. https://doi.org/10.4103/0253-7613.83117
Badar, V A, et al. "Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension." Indian journal of pharmacology vol. 43,4 (2011): 437-40. doi: https://doi.org/10.4103/0253-7613.83117
Badar VA, Hiware SK, Shrivastava MP, Thawani VR, Hardas MM. Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension. Indian J Pharmacol. 2011 Jul;43(4):437-40. doi: 10.4103/0253-7613.83117. PMID: 21845001; PMCID: PMC3153709.
Copy Download .nbib Format: NLM
Share it on

Indian J Pharmacol. 2011 Jul;43(4):437-40. doi: 10.4103/0253-7613.83117.

Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension.

Indian journal of pharmacology

V A Badar, Sachin K Hiware, Meena P Shrivastava, V R Thawani, M M Hardas

Affiliations

  1. Department of Pharmacology, Indira Gandhi Government Medical College, Nagpur, India.

PMID: 21845001 PMCID: PMC3153709 DOI: 10.4103/0253-7613.83117

Abstract

BACKGROUND: Nebivolol is a third-generation β-blocker, with highest β(1) selectivity and nitric-oxide-derived vasodilatation. It also exhibits antiproliferative and antioxidant property that has beneficial metabolic profile compared to second-generation β blockers like atenolol. This study was planned to study the comparative effects of nebivolol and atenolol on metabolic parameters in patients with essential hypertension.

MATERIALS AND METHODS: A prospective, randomized, parallel, open-label clinical study was carried out on patients with essential hypertension. The patients were randomly assigned to receive tablet atenolol (Group A) and nebivolol (Group B) for a period of 24 weeks. Investigations were carried out at baseline and at the end of study period, that is, 24 weeks. Out of 69 patients, 60 completed the study and the data was analyzed using student's t-test. P < 0.05 was considered statistically significant.

RESULTS: Atenolol and nebivolol both showed significant (P < 0.001) antihypertensive action after 24 weeks. Mean blood sugar and lipid profile were found to be significantly (P < 0.001) elevated after 24 weeks of treatment with atenolol but not with nebivolol. Heart rate was significantly (P < 0.001) decreased in both groups at 24 weeks.

CONCLUSION: In view of metabolic adverse effects of atenolol, nebivolol is the better choice whenever β-blockers have to be used in essential hypertension.

Keywords: Atenolol; blood sugar; lipid profile; nebivolol

References

  1. Br J Clin Pharmacol. 1999 Sep;48(3):460-3 - PubMed
  2. Cardiovasc Drugs Ther. 2004 Nov;18(6):469-73 - PubMed
  3. J Hum Hypertens. 1998 Feb;12(2):135-40 - PubMed
  4. J Hypertens. 2008 Feb;26(2):351-6 - PubMed
  5. Lancet. 2005 Sep 10-16;366(9489):895-906 - PubMed
  6. J Hypertens. 2005 Mar;23(3):589-96 - PubMed
  7. J Hypertens. 2006 Mar;24(3):591-6 - PubMed
  8. Heart. 2006 Nov;92(11):1690-1 - PubMed
  9. Drugs. 2010;70(1):41-56 - PubMed
  10. Kardiologiia. 2003;43(2):40-3 - PubMed
  11. J Hum Hypertens. 2001 Oct;15(10):715-21 - PubMed
  12. J Cardiovasc Pharmacol Ther. 2003 Jun;8(2):127-34 - PubMed
  13. Am J Cardiol. 2009 Jan 15;103(2):273-8 - PubMed
  14. Pharmacol Ther. 2003 Dec;100(3):215-34 - PubMed
  15. Blood Press Suppl. 2003 Dec;2:35-40 - PubMed
  16. J Hypertens. 2001 Aug;19(8):1429-35 - PubMed
  17. Am J Health Syst Pharm. 2008 Jun 15;65(12):1125-33 - PubMed
  18. Drugs. 2001;61(4):429-35 - PubMed

Publication Types